Quanterix’s Simoa® Technology Drives Advances in Alzheimer’s Disease Research Presented at 2022 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that its Simoa® technology has powered important advances in ongoing clinical trials for the treatment of Alzheimer’s disease (AD). The findings were presented at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference...
